Inspire Medical Systems, Inc. (INSP)

The long-term investment case is severely compromised by a brutal multi-year decline. Despite a positive cumulative return over the full seven-year window, the company has suffered six consecutive years of negative annual growth, culminating in a staggering 63% drop last year. This trajectory signals a structural deterioration in the business, rendering any current valuation metrics like P/E or book value misleading; the market has already priced in a failing growth story. The recent news of ongoing investigations and board changes further erodes confidence in management's ability to steer the ship. With zero dividends paid over the last five years, there is no income floor to cushion the blow. While the short-term technicals show a slight bounce off lows and the statistical model hints at a modest 6% gain over the next month, this is likely just a mean reversion to a much lower floor rather than a recovery. The options market reflects this tension, with heavy hedging on the downside and speculative bets on a volatile rebound, but the fundamental reality remains bleak.